Jpmorgan Chase & CO Trevi Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 100,517 shares of TRVI stock, worth $278,432. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100,517
Previous 31,350
220.63%
Holding current value
$278,432
Previous $93,000
260.22%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding TRVI
# of Institutions
94Shares Held
57.1MCall Options Held
136KPut Options Held
5.4K-
Nea Management Company, LLC Timonium, MD11.4MShares$31.5 Million2.9% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$20.4 Million1.33% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$13.9 Million0.47% of portfolio
-
Viking Global Investors LP4.4MShares$12.2 Million0.06% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$9.48 Million1.18% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $162M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...